CNSX:BUXBioMark Diagnostics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding BioMark Diagnostics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.16 0.00 (0.00 %) (As of 06/5/2020 01:50 AM ET) Add Compare Share Today's Range$0.17Now: $0.17▼$0.1750-Day Range N/A52-Week Range N/AVolume5,000 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsInsider TradesHeadlines Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions that allows for cancer detection, monitoring, and assessing treatment. The company was incorporated in 2014 and is headquartered in Richmond, Canada. Biomark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for BioMark Diagnostics. Previous Next 2.5 Community Rank Outperform VotesBioMark Diagnostics has received 16 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBioMark Diagnostics has received 16 “underperform” votes. (Add your “underperform” vote.)Community SentimentBioMark Diagnostics has received 50.00% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about BioMark Diagnostics and other stocks. Vote “Outperform” if you believe BUX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BUX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBioMark Diagnostics does not currently pay a dividend.Dividend GrowthBioMark Diagnostics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioMark Diagnostics insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.50 out of 5 stars Industry, Sector and Symbol Stock Exchange CNSX Industry Diagnostics & Research Sub-IndustryN/A SectorMedical Current SymbolCNSX:BUX Previous Symbol CUSIPN/A CIKN/A Webwww.biomarkdiagnostics.com Phone604-370-0779Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable TSXV:BUX Rates by TradingView Receive BUX News and Ratings via Email Sign-up to receive the latest news and ratings for BUX and its competitors with MarketBeat's FREE daily newsletter. BioMark Diagnostics (CNSX:BUX) Frequently Asked Questions Has BioMark Diagnostics been receiving favorable news coverage? Media stories about BUX stock have been trending very negative this week, InfoTrie reports. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. BioMark Diagnostics earned a daily sentiment score of -3.2 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future. View the latest news aboutBioMark Diagnostics. Who are some of BioMark Diagnostics' key competitors? Some companies that are related to BioMark Diagnostics include Carl Data Solutions (CRL), EPIGENOMICS AG/S (EPGNY), Eternity Healthcare (ETAH), Genetic Technologies (GTG), Imagin Medical (IME), Medical Imaging (MEDD), OBJ (OBJ), Parallax Health Sciences (PRLX), Profound Medical (PRN), Sartorius (SRT3) and Siemens Healthineers (SMMNY). View all competitors. Who are BioMark Diagnostics' key executives? BioMark Diagnostics' management team includes the following people: Mr. Rashid Ahmed Bux, Founder, CEO, Pres & DirectorMr. Brian Cheng, CTO & DirectorGina Huang, CFO & Project DirectorDr. Thomas Malcolm Ph.D., Chief Scientific OfficerNeal Kaplan, Chief Financial Officer of US What is BioMark Diagnostics' stock symbol? BioMark Diagnostics trades on the CNSX under the ticker symbol "BUX." How do I buy shares of BioMark Diagnostics? Shares of BUX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is BioMark Diagnostics' stock price today? One share of BUX stock can currently be purchased for approximately $0.17. What is BioMark Diagnostics' official website? The official website for BioMark Diagnostics is www.biomarkdiagnostics.com. How can I contact BioMark Diagnostics? The company can be reached via phone at 604-370-0779. This page was last updated on 6/5/2020 by MarketBeat.com Staff
